Trial Profile

A Phase I, Open-label, Multi-arm, Multi-centre, Multi-dose, Dose Escalation Study of LTX-315 as Monotherapy or in Combination With Either Ipilimumab or Pembrolizumab in Patients With Transdermally Accessible Tumours

Status: Completed

Phase of Trial: Phase I/II

Latest Information Update: 11 Apr 2019

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ipilimumab (Primary) ; Pembrolizumab (Primary) ; Ruxotemitide (Primary)
Indications Advanced breast cancer; Cancer; Head and neck cancer; Lymphoma; Malignant melanoma; Sarcoma; Solid tumours; Triple negative breast cancer
Focus Adverse reactions
Sponsors Lytix Biopharma

03 Apr 2019 Results (n=27) assessing safety and efficacy of LTX-315 in patients with advanced melanoma presented at the 110th Annual Meeting of the American Association for Cancer Research
03 Apr 2019 Results (n=27) from advanced sarcoma cohort were presented at the 110th Annual Meeting of the American Association for Cancer Research.
21 Nov 2018 Results presented in the Lytix Biopharma media release.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com